ArticleNature2026
DCAF11-dependent molecular glue degrader activated by glutathionylation.
Hojong Yoon, Franziska Wachter, Katharine A Barrett, Cyrus Jin, Anna Rodríguez-Pöhnlein, Justine C Rutter, Ryan J Lumpkin, Rebecca J Metivier, Katherine A Donovan, Kheewoong Baek and 7 more
Abstract read
In one paragraphArticle in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Katharine A BarrettDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Cyrus JinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Anna Rodríguez-PöhnleinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ryan J LumpkinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rebecca J MetivierDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Katherine A DonovanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yongying JiangInstitute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Minwoo LeeInstitute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianwei CheDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Funding
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7MA Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer TherapyR00CA287069 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Hojong Yoon · 2025 to 2026
$498kExpanding pharmacological modalities for targeted cancer therapyK00CA253754 · NCI · BROAD INSTITUTE, INC. · PI YOON, HOJONG · 2021 to 2023
$292kA Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer TherapyK99CA287069 · NCI · BROAD INSTITUTE, INC. · PI YOON, HOJONG · 2024 to 2024
$171kNCI NIH HHS K00 CA253754NCI NIH HHS K99 CA287069NCI NIH HHS R00 CA287069NIGMS NIH HHS T32 GM144273
6 · The paper itselfAbstract
Targeted protein degradation is a powerful pharmacological strategy that harnesses the ubiquitin proteasome system to eliminate disease-relevant proteins, including otherwise undruggable proteins
Indexed as
GlutathioneProdrugsProteolysisUbiquitin-Protein LigasesAnimalsBinding SitesGlutathione TransferaseHEK293 CellsHumansProteolysis Targeting ChimeraSubstrate SpecificityGlutathioneGlutathione TransferaseProdrugsProteolysis Targeting ChimeraUbiquitin-Protein Ligases
Identifiers
PMID42557329
PMCPMC13600927
What OpenQuestion holds
Textmetadata
Read underepoch 390